Synthetic Lethality in Cancer Therapeutics - OICR Mondays

Moderator: Dr. Charlie Boone, University of Toronto

10:12 - Clinical perspective: Success of and development of resistance to current synthetic lethal drugs (PARP inhibitors) and emerging synthetic lethal drugs in the clinic. (Dr. Stéphanie Lheureux, UHN)

34:12 - SL target identification and biomarker perspective: Screening methods to identify synthetic lethal interactions and development of biomarkers for patient stratification and/or combination therapies. (Dr. David Gallo, Repare Therapeutics)

55:40 Druggability perspective: Opportunities and challenges in drugging new synthetic lethal drug targets – not all genes are created equally. (Dr. Richard Marcellus, OICR Drug Discovery Program)